Dacogen

 

Topic mentions per year

Topic mentions per year

2003-2015
0246820032015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
UNLABELLED : On September 20, 2012, a marketing authorization valid throughout the European Union (EU) was issued for decitabine… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Epigenetic alterations are a hallmark of cancer that govern the silencing of genes. Up to now, 5-azacytidine (5-aza-CR, Vidaza… (More)
  • table 1
Is this relevant?
2013
2013
TO THE EDITOR: Sekeres and Steensma describe the US Food and Drug Administration Oncologic Drug Advisory Committee (ODAC)’s… (More)
Is this relevant?
2012
2012
As specialists in adult leukemia, we have grown accustomed to the jibes from oncologists focused on other diseases: “So are you… (More)
Is this relevant?
2010
2010
C R E D IT S ( T O P T O B O T T O M ): J O E R U B IN O ; P H O T O C O U R T E S Y O F U S C with a potent cancer cell–killing… (More)
Is this relevant?
2008
2008
As we learn more about the role of chromatin structure and function in cancer, the ability to treat tumors by targeting… (More)
  • figure 1
Is this relevant?
2006
2006
OBJECTIVE Treatment with the DNA demethylating drug 5-aza-2'-deoxycytidine (Dacogen; DAC) increased fetal hemoglobin and F cells… (More)
Is this relevant?
2005
2005
Azanucleoside drugs such as 5-azacytidine (Vidaza) and 5-aza-2'-deoxycytidine (decitabine, Dacogen) function as DNA… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2004
2004
Epigenetic alterations, such as aberrant DNA methylation and histone deacetylation, can silence genes that suppress… (More)
Is this relevant?
2004
2004
The antineoplastic activity of 5-aza-2'-deoxycytidine (5-AZA-CdR) and docetaxel (Taxotere, Taxo) alone or in combination against… (More)
Is this relevant?